For a pandemic-free world
Lovaltech is a French DeepTech start-up founded in 2022 to carry forward the ambitious research project of the University of Tours and INRAE.
We are committed to the industrial development of a new generation of protein-based nasal vaccines, and our first vaccine will enter clinical trials as early as March 2025 (https://clinicaltrials.gov/study/NCT06821126).
